---
title: "Foyou Pharma: Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) has obtained the drug registration certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/259278170.md"
description: "Foyou Pharma recently obtained the drug registration certificate for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) issued by the National Medical Products Administration, approving the production of this drug. This drug is a compound preparation that contains Candesartan Cilexetil and Hydrochlorothiazide, suitable for adults with primary hypertension who cannot effectively control their blood pressure"
datetime: "2025-09-29T08:08:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259278170.md)
  - [en](https://longbridge.com/en/news/259278170.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259278170.md)
---

# Foyou Pharma: Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) has obtained the drug registration certificate

According to the Zhitong Finance APP, Foyou Pharma (601089.SH) announced that it has recently received the "Drug Registration Certificate" (Certificate No.: 2025S02994) issued by the National Medical Products Administration (referred to as "NMPA") for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) (Specification: Each tablet contains 16mg of Candesartan Cilexetil and 12.5mg of Hydrochlorothiazide), approving the production of this drug.

Candesartan Cilexetil and Hydrochlorothiazide is a compound formulation consisting of the angiotensin II receptor inhibitor Candesartan Cilexetil and the diuretic Hydrochlorothiazide, jointly developed by Takeda and AstraZeneca, and was first launched in Sweden in June 1998, receiving FDA approval in the United States in September 2000. Currently, the original manufacturer’s Candesartan Cilexetil and Hydrochlorothiazide Tablets have not been launched in China. This product is not suitable for the initial treatment of hypertension and is indicated for adults with primary hypertension whose blood pressure cannot be effectively controlled by either Candesartan Cilexetil or Hydrochlorothiazide alone, or as a substitute treatment at the same dosage for the combination of both drugs

### Related Stocks

- [601089.CN](https://longbridge.com/en/quote/601089.CN.md)

## Related News & Research

- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [Chemtrade Logistics Holds Guidance Amid Commodity Swings](https://longbridge.com/en/news/286831060.md)
- [PRECIOUS-Gold falls more than 2% as Treasury yields, dollar weigh amid inflation concerns](https://longbridge.com/en/news/286943432.md)
- [PRECIOUS-Treasury yields, dollar weigh on gold amid inflation concerns](https://longbridge.com/en/news/286929968.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)